Holen Sie sich die Stockscreener-App
11.53
1.86%
0.21
Handel nachbörslich:
11.60
0.07
+0.61%
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Zevra Therapeutics (ZVRA) insider sells 42,666 shares - Stock Titan
Price-Driven Insight from (ZVRA) for Rule-Based Strategy - Stock Traders Daily
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Stocktwits
Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker - Stock Titan
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position - Stock Titan
Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA - TradingView
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc.ZVRA - PR Newswire
Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock - MarketBeat
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therape - The National Law Review
Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Reach Out - accessnewswire.com
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data - Sahm
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Zevra Therapeutics, Inc. (ZVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
ZVRA Maintained by Guggenheim -- Price Target Lowered to $23.00 - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim - MarketBeat
FY2026 EPS Forecast for Zevra Therapeutics Raised by Analyst - MarketBeat
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: A Biotech Stock with 113% Potential Upside - DirectorsTalk Interviews
What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review? - Yahoo Finance
ZVRA Maintained by Citizens -- Price Target Raised to $28.00 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Investors to Connect - accessnewswire.com
Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 14.1% on Better-Than-Expected Earnings - MarketBeat
Zevra Therapeutics (ZVRA) gains FMR LLC and Abigail Johnson 8.3% stake disclosure - Stock Titan
Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.11, Implies 138% Upside - TradingView
Zevra Therapeutics Q2 Earnings Call Highlights - MarketBeat
Citizens Jmp Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights - GuruFocus
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ... - Yahoo Finance
ZVRA Looks 54.4% Undervalued on GF Value™ at $10.54 - GuruFocus
Earnings call transcript: Zevra beats Q2 2026 estimates as MIPLYFFA sales rise - Investing.com
ZVRA Looks 54.4% Undervalued on GF Value™ as Market Weighs Q2 Re - GuruFocus
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Is Zevra Therapeutics Inc (ZVRA) Underperforming After Q2 2026 E - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Announces Quarterly Earnings Results - MarketBeat
Zevra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat - Quiver Quantitative
ZEVRA THERAPEUTICS, INC. 2026: Revenue $39.66M, EPS $0.14— 10-Q Summary - TradingView
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) posts Q2 profit, repays debt - Stock Titan
Zevra Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales - TradingView
Zevra Reports Q2 2026: $39.7M Revenue, $8.8M Net Income, $260.2M Cash - TradingView
Zevra Therapeutics, Inc. (ZVRA) Q2 FY2026 earnings call transcript - Yahoo Finance
Press Release: Zevra Reports Second Quarter 2026 Financial Results and Corporate Update - Moomoo
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics, Inc. (ZVRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
(ZVRA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Zevra Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
ZVRA: Strong H1 2026 revenue and cash position support growth in rare disease therapeutics - TradingView
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference - The Manila Times
Zevra executives set to present at Boston growth conference - Stock Titan
Zevra Therapeutics (ZVRA) Securities Investigation NoticeLevi & Korsinsky - Morningstar
Zevra Therapeutics Announces Publication of 4-Year Real-World Data on MIPLYFFA in Niemann-Pick Disease Type C - Quiver Quantitative
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) - The Manila Times
Vanguard Capital Management (ZVRA) discloses 3.0M-share Zevra Therapeutics position on 13G - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA) - businesswire.com
ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics - Morningstar
BTIG cuts Zevra Therapeutics price target on EU setback - Investing.com
BTIG cuts Zevra Therapeutics price target on EU setback By Investing.com - Investing.com Canada
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics - Bitget
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):